发明名称 |
Genetic marker of response to atypical antipsychotics and antidepressants and methods for use thereof |
摘要 |
The invention provides methods of identifying candidate psychiatric patients, or patients with movement disorder, for treatment with receptor site or increases density of D2 dopamine receptors. The method comprises determining a patient's DRD2 genotype. Patients having the Taq1A (A1) allele (A1+ allelic status) are candidates for treatment with high dose, high binding antipsychotics and/or SSRIs that influence D2 receptor density. Patients lacking the Taq1A allele (A1- allelic status) are candidates for treatment with low dose, low binding atypical antipsychotics, and are not likely to respond well to these SSRIs. |
申请公布号 |
AU2004258147(B2) |
申请公布日期 |
2009.04.30 |
申请号 |
AU20040258147 |
申请日期 |
2004.07.08 |
申请人 |
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;THE UNIVERSITY OF QUEENSLAND;STATE OF QUEENSLAND ACTING THROUGH QUEENSLAND HEALTH |
发明人 |
ERNEST P. NOBLE;ROSS M. YOUNG;BRUCE R. LAWFORD |
分类号 |
C12Q1/68;C07H21/04;C12N15/00;C12P19/34;C12Q |
主分类号 |
C12Q1/68 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|